Gabather files two new patent applications to secure novel findings on the effects of GT-002 for the treatment of psychiatric disorders
STOCKHOLM, March 18, 2024 -- Gabather AB (Nasdaq First North Growth Market: GABA) today reports that two new US provisional patent applications based on novel findings from the EEG/fMRI target engagement study with GT-002, a selective positive allosteric GABAA-receptor modulator. The inventions relate to the medical use of GT-002 in psychiatric disorders.The claims based on inventions from the results from our EEG/fMRI target engagement study are both novel and unexpected and will strengthen Gabather’s intellectual property right (IPR) position in the field of GABA\A\ receptor modulators,